|With the popularity and success of our Biotech “Trade Ideas,” we are expanding to provide you with daily Trade Ideas researched by our team. We will now be adding Tech “Trade Ideas” to your service. Tech is set be volatile into the rest of the fiscal year with trade wars creating unprecedented opportunity. A 3%+- rally is only a tweet away in today’s market. Let’s capture that opportunity before it happens. Please let us know if you have any questions!|
1). TGT – Puts
*Had a well received ER, currently up 20%. Tariffs anticipated to come into effect September 1st. Should this happen a significant amount of TGT supply chain will be impacted and will be reflected in price
2). SHOP – Short term bull
*up 170% YTD and 1200% since IPO. Should current market conditions hold for the month of April, $405 appears to be a reasonable target.
3). AAPL – Puts
*Couldn’t hold key resistance. The last time this happened (AUG 14th) AAPL lost -0.5% the following day. Watching for pump up to new Iphone release in a longer view. Watching for short term touch at $214 and retrace to $208
4). BIDU – Puts
*ER is causing some criticism after previous guidance. Investors working these points out may benefit from continued pullback after the ER pop. This may be further inflated by a pull back on SPY.
*Recent “Buy Ratings” from Citigroup. Held above 200DMA at close. Options expiring Friday may continue to keep price down, be cognizant of the levels created by that.
6). AMD – Calls/Puts
*Closed at high of day. Watching for continuation tomorrow and Puts around the $32 range depending on price action. Historically the indexes have rejected the levels we are running towards, suggesting a sell of which will drastically improve gains on a bearish measure.
7). MSFT – Puts
*Looking for pullback after recent rally. Up 35%+ for the year but still faces looming risk/ potential news with trade tensions. Will be damaged by pullback on SPY.
Up Coming ER’s
8/21 Baozun (BZUN)Analyst rating; buy, avg pt: $55.68Target (TGT)Analyst rating; hold, buy, avg pt: $89.65Lowe’s Companies (LOW)Analyst rating; buy, avg pt: $113.97
8/22 Salesforce.com (CRM)Analyst rating; buy, avg pt: $182.92Gap (GPS)Analyst rating; hold, avg pt: $21.11Dick’s Sporting Goods (DKS)Analyst rating; hold, avg pt: $37.38
8/23 Sesen Bio (SESNAnalyst rating; buy, avg pt: $3.58Ability (ABIL)Analyst rating; hold, avg pt: $1.3Just because a company is listed higher on the email does not necessarily mean its a better stock to trade.
* Our daily “Trade Ideas” emails are meant to give you ideas for swing and day trades. Returns we aim for are in the mid-single-digit to the double-digit range. Price targets (PT) are short-term in nature (i.e. a few days to a few weeks). Don’t be afraid to sell before the PT is hit if you are up on the position. Price targets are estimates, not an exact science.
MS Money Move and its Chief Operating Officer who is a scientist and individual investor, as well as its affiliates are not registered financial advisors. Our posts should serve as educational material to help you conduct due diligence research. Posts and articles are not directives or recommendations to invest in any security. We reserve the right to buy or sell any security for ourselves without any notification except when required by law. We are not responsible for the action of our affiliates. Investment theses may change due to the variable nature of the securities market. Because of this there is great risk when investing in stocks and options which can result is capital loss. Additionally, past performance by MS Money Moves or any security is not a predictor of future performance. Everyone should conduct their own research and due diligence before making an investment decision. We recommend you consult a financial advisor regarding any investment action.
The biotech sector is especially volatile. Stock prices may fluctuate substantially based on material or nonmaterial developments. We encourage everyone to familiarize themselves with clinical trial processes, relevant terminology, FDA/SEC rules and regulations, and the general processes of drug & therapy development/approval. Always do independent research in a security prior to investing.